EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Preimplantation genetic diagnosis for retinoblastoma survivors: a cost-effectiveness study

D Schofield, M J B Zeppel, S Staffieri, R N Shrestha, D Jelovic, E Lee, R V Jamieson

Reproductive Biomedicine & Society Online · 2020-06 · 10 · 37-45

DOI: 10.1016/j.rbms.2020.03.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Reproductive Biomedicine & Society Online, 2020-06. Verfasst von D Schofield und 6 weiteren Autor:innen. Beteiligte Einrichtung: GenIMPACT, Centre for Economic Impacts of Genomic Medicine, Faculty of Business and Economics, Macquarie University, Sydney, Australia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to investigate the cost-effectiveness of preimplantation genetic diagnosis (PGD) for the reproductive choices of patients with heritable retinoblastoma. The study modelled the costs of three cycles of in-vitro fertilization (IVF) and PGD across all uptake rates of PGD, number of children affected with retinoblastoma at each uptake rate and the estimated quality-adjusted life years (QALYs) gained. Cost-effectiveness analysis was conducted from the Australian public healthcare perspective. The intervention was the use of three cycles (one fresh and two frozen) of IVF and PGD with the aim of live births unaffected by the retinoblastoma phenotype. Compared with the standard care pathway (i.e. natural pregnancy), IVF and PGD resulted in a cost-saving to 18 years of age of AUD$2,747,294 for a base case of 100 couples with an uptake rate of 50%. IVF and PGD resulted in fewer affected (n = 56) and unaffected (n = 78) live births compared with standard care (71 affected and 83 unaffected live births), and an additional 0.03 QALYs per live birth. This modelling suggests that the use of IVF and PGD to achieve an unaffected child for patients with heritable retinoblastoma resulted in an overall cost-saving. There was an increase in QALYs per baby across all uptake rates. However, in total, fewer babies were born following the IVF and PGD pathway.

Schlagwörter

Stichwörter der Autor:innen

assisted reproductive technologyautosomal-dominant diseasecost-effectivenessin-vitro fertilizationpreimplantation genetic diagnosisretinoblastoma

Autor:innen und Institutionen

  • GenIMPACT, Centre for Economic Impacts of Genomic Medicine, Faculty of Business and Economics, Macquarie University, Sydney, Australia.
  • Department of Ophthalmology, Royal Children's Hospital, Parkville, Australia.
  • Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
  • Ophthalmology, University of Melbourne, Department of Surgery, East Melbourne, Australia.
  • Eye Genetics Research Unit, The Children's Hospital at Westmead, Children's Medical Research Institute, Save Sight Institute, University of Sydney, Sydney, Australia.
  • Discipline of Genomic Medicine, The Children's Hospital at Westmead Clinical School, University of Sydney, Sydney, Australia.

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Schofield, D., Zeppel, M. J. B., Staffieri, S., Shrestha, R. N., Jelovic, D., Lee, E., & Jamieson, R. V. (2020). Preimplantation genetic diagnosis for retinoblastoma survivors: a cost-effectiveness study. Reproductive Biomedicine & Society Online, 10, 37-45. https://doi.org/10.1016/j.rbms.2020.03.001

Vancouver

Schofield D, Zeppel MJB, Staffieri S, Shrestha RN, Jelovic D, Lee E, et al. Preimplantation genetic diagnosis for retinoblastoma survivors: a cost-effectiveness study. Reproductive Biomedicine & Society Online. 2020;10:37-45. doi:10.1016/j.rbms.2020.03.001

BibTeX
@article{Schofield2020,
  author = {Schofield, D and Zeppel, M J B and Staffieri, S and Shrestha, R N and Jelovic, D and Lee, E and Jamieson, R V},
  title = {Preimplantation genetic diagnosis for retinoblastoma survivors: a cost-effectiveness study},
  journal = {Reproductive Biomedicine & Society Online},
  year = {2020},
  volume = {10},
  pages = {37--45},
  doi = {10.1016/j.rbms.2020.03.001}
}
Kostenlos starten →